FFA
UBX

Farther Finance Advisors’s Unity Biotechnology UBX Stock Holding History

Farther Finance Advisors’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20
Closed -$27 – 4126
2024
Q2 		$27 Buy
+20
New +$30 ﹤0.01% 3742

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return

Farther Finance Advisors's UBX Position: Q3 2024 in Review

Farther Finance Advisors sold out of Unity Biotechnology (UBX) in Q3 2024, closing a stake of 20 shares — an estimated $27 sold.

Farther Finance Advisors first reported a position in UBX in Q2 2024 and held it in 1 quarter. The position peaked at $27 in Q2 2024. 38 funds tracked by Wall St. Rank hold UBX as of Q3 2024.

  • Farther Finance Advisors reported no remaining Unity Biotechnology position as of Q3 2024 after selling out during the quarter.
  • Farther Finance Advisors sold 20 Unity Biotechnology shares in Q3 2024, an estimated $27.
  • Farther Finance Advisors first reported a position in Unity Biotechnology in Q2 2024 and held it in 1 quarter.
  • Farther Finance Advisors's Unity Biotechnology position peaked at $27 in Q2 2024.
  • 38 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2024.

Based on Farther Finance Advisors's 13F filing for Q3 2024, filed 29 Oct 2024.